Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BLISOVI 24 FE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women ≥14 years (only if desiring contraception),Treatment of premenstrual dysphoric disorder (PMDD) in women of reproductive age
Prevention of pregnancy (FDA-approved)
One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Drospirenone: 25-33 hours; Ethinyl estradiol: 13-24 hours; steady-state achieved after 10 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes hydroxylation via CYP3A4 and conjugation (glucuronidation, sulfation); drospirenone is metabolized primarily via CYP3A4 and to a lesser extent via CYP1A1 and CYP2C9.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 30-40% as drospirenone metabolites, 20-30% as ethinyl estradiol metabolites; fecal: 40-50% as drospirenone metabolites, 30-40% as ethinyl estradiol metabolites; biliary: minimal.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Drospirenone: 95-97% bound to albumin; Ethinyl estradiol: 98% bound to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Drospirenone: 4 L/kg; Ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Drospirenone ~76%; Ethinyl estradiol ~45% (first-pass metabolism reduces absolute bioavailability).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min/1.73 m²) due to potential fluid and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh A), use with caution and monitor liver function; dose adjustment not specifically defined.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 24 weeks followed by placebo for 4 weeks.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific geriatric dose studies; use not recommended in elderly due to lack of indication.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders and cardiovascular events (including VTE, MI, stroke),Liver disease (including hepatic adenoma or active hepatitis),Hypertension (especially new-onset or uncontrolled),Carbohydrate and lipid metabolism effects,Headache (including migraine with focal neurological symptoms),Bleeding irregularities (e.g., breakthrough bleeding, amenorrhea),Depression,Gallbladder disease,Hereditary angioedema exacerbation,Chloasma,Drug interactions (e.g., anticonvulsants, antibiotics, St. John's Wort)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Active liver disease or hepatic adenoma,Uncontrolled hypertension (BP >160/100 mm Hg),Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35,Breast cancer or other estrogen-sensitive neoplasms,Undiagnosed abnormal uterine bleeding,Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir,Severe renal insufficiency or adrenal insufficiency (due to drospirenone's K+-sparing diuretic effect),Smoking in women >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is not established. The iron tablets should be taken with food if gastrointestinal upset occurs; avoid taking with calcium-rich foods or beverages (e.g., milk) as they may reduce iron absorption.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
BLISOVI 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy due to increased risk of fetal harm, including cardiovascular anomalies and neural tube defects during first trimester. No evidence of teratogenicity from inadvertent exposure, but risk of oral clefts and heart defects with first trimester use. Later trimester exposure may be associated with genitourinary anomalies and potentially metabolic effects.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio approximately 0.4-0.7. May reduce milk production, especially in early postpartum. Benefit-risk assessment required; consider alternative contraception for lactating women.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustment in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased clearance, decreased protein binding) may reduce efficacy; not applicable due to contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
BLISOVI 24 FE is a combination oral contraceptive containing drospirenone and ethinyl estradiol, with ferrous fumarate as an iron supplement in the fourth week. The drospirenone component has anti-mineralocorticoid activity, which may cause mild potassium elevation; caution in patients with renal impairment or on potassium-sparing diuretics. Missed pills in week 1 warrant a backup method. The iron tablets are placebo for contraception; ensure patient does not mistake them for active pills.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time. The last 4 tablets in the pack are iron tablets, not active hormones; they do not provide contraception.,If you miss one active pill, take it as soon as remembered and continue the pack. If you miss two active pills in a row, take the last missed pill, discard the other, use backup contraception for 7 days.,Smoking increases risk of serious cardiovascular side effects, especially in women over 35. Avoid smoking while on this medication.,Inform your healthcare provider if you have kidney disease, liver disease, adrenal insufficiency, or if you take potassium-sparing diuretics (e.g., spironolactone) due to potential potassium elevation.,Common side effects include nausea, breast tenderness, headache, and spotting between periods. These often improve after a few cycles.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BLISOVI 24 FE vs AFIRMELLE, answered by our medical review team.
BLISOVI 24 FE is a Oral Contraceptive that works by Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BLISOVI 24 FE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BLISOVI 24 FE is: One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BLISOVI 24 FE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BLISOVI 24 FE is classified as Category C. BLISOVI 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy due to increased risk of fetal harm, including cardiovascular anomalies and neural tube defects duri. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.